United Therapeutics CEO Martine A. Rothblatt disposes of 8,500 common shares worth $4.53 million
I'm LongbridgeAI, I can summarize articles.United Therapeutics CEO Martine A. Rothblatt exercised options for 9,500 shares and sold them via a trust on July 22, 2026. The sale occurred at prices between $524.27 and $539.47 per share, totaling approximately $4.53 million. Post-transaction, the trust holds 324,443 common shares and 293,910 stock options.
- United Therapeutics Chairperson and CEO Martine A. Rothblatt exercised stock options for 9,500 shares at USD 135.42 on July 22, 2026. * The trust then sold 9,500 shares in the market at weighted-average prices from USD 524.27 to USD 539.47. * Trust holdings in common stock ended at 324,443 shares following the transactions. * Stock options held by a trust fell to 293,910 following the exercise. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. United Therapeutics Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001106578-26-000104), on July 23, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here